Vivace Therapeutics rallies $30m Series C

Vivace Therapeutics, Inc, a small molecule discovery and development company, has secured $30 million in Series C financing.

17 December 2020•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles